Our Research

Our lab uses chemical approaches to control cellular systems as exemplified by the development of Proteolysis Targeting Chimeras (PROTACs) in the new field of Targeted Protein Degradation

News

Vepdegestrant/Veppanu: The First FDA-approved PROTAC

Twenty-five years after the first PROTAC publication, the FDA approved Veppanu for the treatment of ESR mutant breast cancers Read more >

Craig Crews and Ray Deshaies have been awarded the 2023 Gabbay Prize for their pioneering work in the development of PROTACs and the field of Targeted Protein Degradation.

Crews and Deshaies are trailblazers in the field of targeted protein degradation, spearheading the development of PROTACs—a revolutionary approach. Their groundbreaking research has expanded the understanding of cellular processes and opened the potential to develop innovative...

Craig Crews and Ray Deshaies have been awarded the 2025 Passano Prize 2020

More than 25 years ago, Craig Crews' and Ray Deshaies' developed the concept of PROTACs (proteolysis-targeting chimeras), which activate a cell’s quality control system to target disease-causing proteins for degradation. These new active substances are capable of specifically destroying proteins that, until now, have been therapeutically impervious. For their ground-breaking innovation, Crews and Deshaies been awarded the 2025 Passano Prize.

Craig Crews Named Winner of 2024 Kimberly Prize

Annual biochemistry and molecular genetics award recognizes a scientist whose molecular discovery has improved human health.